For treatment in preclinical models of stroke or PD in the mouse, an 8D3-derived TfRMAb–TNFR fusion protein was engineered and expressed, and this fusion protein retained high affinity binding to both the mouse TfR1 and TNFα [783]. The gene discussed is TNFRSF1A; the disease is stroke disorder.